99979-77-8

Basic information

• Product Name: 2-Chloro-5-Methoxy-pyriMidin-4-ylaMine
• Synonyms: 2-Chloro-5-Methoxy-pyriMidin-4-ylaMine;2-chloro-5-MethoxypyriMidin-4-aMine;2-Chloro-5-Methoxy-4-pyriMidinaMine
• CAS NO: 99979-77-8
• Molecular Formula: C₅H₆ClN₃O
• Molecular Weight: 159.57364
• Mol File: 99979-77-8.mol
• Article Data: 5

Chemical Properties

• Melting Point: 181-182 °C (decomp)(Solv: ligroine (8032-32-4))
• Boiling Point: 349.6±22.0 °C(Predicted)
• Appearance: /
• Density: 1.398±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.39±0.10(Predicted)
• CAS DataBase Reference: 2-Chloro-5-Methoxy-pyriMidin-4-ylaMine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-5-Methoxy-pyriMidin-4-ylaMine(99979-77-8)
• EPA Substance Registry System: 2-Chloro-5-Methoxy-pyriMidin-4-ylaMine(99979-77-8)

Safety Data

• Hazardous Substances Data: 99979-77-8(Hazardous Substances Data)

Usage

Uses

The preparation and synthesis of 2-Chloro-5-methoxy-4-pyrimidinamine.

Upstream product

• 19646-07-2 2,4-dichloro-5-methoxypyrimidine 

Downstream Products

• 1349829-86-2 2-((2R,5R)-2-methyl-5-phenylmorpholino)-6H-pyrimido[5,4-b][1,4]oxazin-7(8H)-one 
• 943995-32-2 2-chloro-6H,7H,8H-pyrimido [5,4-b][1,4]oxazin-7-one 
• 1349829-61-3 2-bromo-6H-pyrimido[5,4-b][1,4]oxazin-7(8H)-one 
• 219715-62-5 2-amino-5,8-dimethoxy[1,2,4]triazolo-[1,5-c]pyrimidine 

Relevant articles and documents

Fused pyrimidine ring derivative, preparation method therefor and application thereof

The invention discloses a type of fused pyrimidine ring derivatives shown in a formula (I) acting as a tyrosine kinase inhibitor and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, A and B are as defined in the description. The inve

FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY

A series of substituted benzimidazole, imidazo[1,2-a]pyridine and pyrazolo[1,5-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES

The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.